Being for the $11.9bn benefit of investors of Kite: Gilead jumps into CAR-T
Gilead will add a late-stage CAR T-cell candidate and a facility in California capable of treating 5,000 patients per year through the $11.9bn deal.
Gilead will add a late-stage CAR T-cell candidate and a facility in California capable of treating 5,000 patients per year through the $11.9bn deal.
Keystone Folding Box Co. has designed a new child-resistant paperboard pack, which it says fits in line with manufacturer’s sustainability objectives.
Eurofins Pharma Bioanalytical Services has launched a consulting program to support clients conducting large molecule preclinical and clinical studies.
Ajinomoto Althea, Inc. has added a new aseptic fill/finish line in response to client's concerns regarding active pharmaceutical ingredient (API) manufacturing costs.
President Trump has signed the FDA Reauthorization Act into law, reauthorizing four user fee agreements and reducing CMO burden, says PBOA.
Alembic Pharmaceuticals Limited has sold its drug plant in Baddi, Himachal Pradesh to Scott Edil Pharmacia Limited.